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onary artery bypass graft and 25 % had previous coronary angioplasty. At the
time of valve implantation, 35 % of pts had at least one significant coronary
stenosis (> 50 %). TAVR was performed under local anesthesia after surgical
cut-down of the femoral artery. A 23 or 26 mm transcutaneous valve was
implanted during a brief period of rapid pacing (200 to 220 bpm). Cardiac
Troponin I was measured using the DPC Immulite 2500 assay (lower limit of
detection: 0.2 μg/l, suggested diagnostic value for myocardial infarction: 1.0
μg/l) before, 8 hours and 24 hours after TAVR.
Results: After TAVR, the effective orifice area increased from 0.64 ± 0.14
to 1.80 ± 0.3 cm2 (p< 0.0001) and the transvalvular mean gradient decreased
from 47 ± 15 to 8 ± 4 mmHg (p<0.0001). Troponin level was 0.07 ± 0.15 μg/
l at baseline and significantly increased 8 hours (2.57 ± 2.47 μg/l) and 24
hours (4.82 ± 8.02 μg/l) after TAVR (p<0.001). Troponin level was above 1.0
μg/l in 45 (88%) pts. No pts exhibited new pathological Q-waves.
Conclusions: Moderate elevations in troponin are common after TAVR.
These data should help to define the level of troponin elevation indicating
periprocedural myocardial infarction. Whether increase in troponin level after
TAVR has a prognostic impact remains to be determined in a larger population.
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Purpose: There is a paucity of data regarding consequences of mitral
stenosis (MS) on respiratory function and exercise capacity. In view of fre-
quent discrepancies between symptoms and anatomy in MS, identification of
determinants of aerobic capacity could be useful in the clinical-decision
making process. Our objective was to evaluate the role of cardiac and pulmo-
nary alterations on aerobic capacity in MS.
Methods: Twenty-eight patients (53±7 y) with history of MS were pro-
spectively included. A comprehensive echocardiography was performed at rest
and during exercise. Right ventricular (RV) systolic function was assessed
with tricuspid lateral annulus S wave velocity (STric). Respiratory function
was assessed at rest with measure of transfer of carbon monoxide (DLCO).
We analyzed the two components of DLCO: membrane diffusion (DM) and
capillary volume (VCAP). Maximal oxygen uptake (VO2max) was determined
during cardio-pulmonary exercise test.
Results: Ten patients were examined before (native MS group) and 18
after corrective treatment (treated MS group). The mitral valve functional area
(MVA) was 1.3±0.3 cm2 in native MS group and 1.6±0.1 cm2 in treated MS
group. Overall, NYHA class was 1.8±0.3, VO2max 18±3 ml/kg/min, maximal
workload 85±13 Watts. There were no differences between groups in NYHA
class, maximal workload, VO2max, trans-mitral and trans-tricuspid gradients
and DLCO. DM and VCAP were impaired in patients with a history of MS.
In univariate analysis determinants of VO2max were gender (r=0.6, p=0.001),
DM (r=0.65, p=0.04), VCAP (r=0.69, p=0.001), exercise cardiac output
(r=0.55, p=0.003), and exercise STric (r=0.56, p=0.008). In multivariate anal-
ysis, independent determinants of VO2max were exercice STric (r=0.55,
p=0.005) and VCAP (r=0.46, p=0.01).
Conclusion: DM and VCAP are impaired in MS. RV contractile reserve
and VCAP are the main determinants of aerobic capacity in MS. Theses
parameters could be used in the clinical-decision making process in MS.
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Background: Prosthetic valve endocarditis (PVE) is a rare and serious
complication after heart valve replacement. Despite progress in therapeutic
modalities, morbidity and mortality remain untolerably high.
Objective: to evaluate the current outcome of PVE in a high volume ter-
tiary care center in Tunisia and to analyse predictors of mortality.
Methods: All cases of PVE treated in our institution between 1997 and
2008 were analysed according to the modified DUKE criteria. Univariate and
multivariate analysis were performed to assess predictors of mortality. Two
sided p values<0.05 were considered significant.
Results: During the study period, 234 IE were diagnosed, among them
74 were PVE (42 males and 32 females), mean age was 39.23 years. They
were early PVE in 38 cases (51.4%) and late PVE in 36 cases (48.6%).
28 patients (38.7%) underwent surgical intervention during the active
phase. 14 patients died during index hospitalization (i.e. 18.9% in hospital
mortality).
In comparison with survivors, patients who died had a considerably longer
delay to diagnosis (18.9 days vs 8.89; p=0.03), more hyperleucocytosis (14678
vs 10234; p=0.015) and more severe anemia (8.56 g/dl vs 10.46g/dl). They
suffered considerably more congestive heart failure (78.6% vs 10%; p<0.001)
and were more likely to undergo surgery during the active phase (71% vs
30%; p=0.006).
Echocardiographically, patients who died presented more frequently highly
mobile vegetations (63.8% vs 17.8%; p=0.005), massive vegetations (>15mm)
(44.4% vs 4.2%; p=0.013), annular abscess (38.5% vs 1.7%; p<0.001), pros-
thetic dehiscence (42.9%vs 17.3%;p=0.049) and prosthetic abscesses (28.6%
vs 3.8%;p<0.001).
Conversely, neither age nor causative organisms were associated with in
hospital mortality.
On multivariate analysis, the only variable strongly correlated with in hos-
pital death was congestive heart failure (HR=27.5, p=0.005, 95% CI [2.78-
276.6]).
Conclusion: PVE remains very serious condition carrying high mortality
rates.In our series, the strongest predictor of mortality was congestive heart
failure.
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Background: Despite improvements in medical and surgical therapy,
infective endocarditis (IE) is still associated with a severe prognosis and
remains a therapeutic challenge. We aimed to evaluate the impact of a stan-
dardized diagnostic and therapeutic protocol on mortality and to correlate the
outcome with the compliance to our management-based protocol.
Methods: Observational before-after study including 333 consecutive
patients treated for IE at a referral center conducted from 1991 to 2006 and
divided in two periods: period 1 (1991 to 2001), before implementation of
our therapeutic protocol (n=173) and period 2 (2002 to 2006) after imple-
mentation of our protocol (n=160) created by a multidisciplinary task force
including a sampling of biological specimens, the use of only four antimi-
crobials, a standardized duration of treatment, standardized surgical indica-
tions, and one year follow-up. Because our protocol was based on a local
consensus by physicians and surgeons, it was impossible to randomize the
study.
Results: The one-year mortality significantly decreased from 18.5% during
period 1 to 8.2% during period 2 (hazard ratio=0.41; 95% confidence interval,
© Elsevier Masson SAS. All rights reserved.
 
58 Archives of Cardiovascular Diseases Supplements (2010) 2, 50-60
0.21-0.79; p=0.0075). After multivariable analysis, the management during the
period 2 remained a strong protective factor (adjusted hazard ratio=0.26; 95%
confidence interval, 0.09-0.76; p=0.014). During period 2, we observed a sig-
nificant better compliance in antimicrobial therapy and fewer cases of renal
failure. Deaths by embolic events and multiple organ failure syndrome also
significantly decreased during period 2.
Conclusions: A dramatic reduction in mortality was observed during this
study suggesting that a management-based approach has a significant impact
on IE outcome. 
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Introduction: Percutaneous mitral valvuloplasty (PVM) is an effective
therapy for mitral stenosis in selected patients. Nonetheless, mitral valve
replacement (MVR) may be still required after PVM in some cases. The aim
of this analysis is to assess predictors of MVR after PVM.
Methods: Our retrospective study includes 354 patients enrolled in our
department (1996-2002).
Results: Thirty seven (10, 34%) of 354 patients underwent MVR at a mean
interval of 13,6±9,3 months after PVM. No major differences were apparent
in the demographic features of patients who did or did not undergo surgery.
Five patients (13%) underwent surgery within the first month after PVM while
32 patients (87%) were operated later. On univariate analysis several predic-
tors were brought out: rheumatic antecedents, commissurotomy history, atrial
fibrillation, severe mitral regurgitation before PVM or its aggravation after
PVM, high echocardiography score, calcification, small mitral area, mitral gra-
dient, diastolic and systolic arterial pulmonary pressure before PVM. How-
ever, on multivariate analysis only mitral area, diastolic and systolic arterial
pulmonary pressure could be predictors for surgery.
Conclusion: Certainly, PVM is an excellent treatment option in mitral
stenosis. It is minimally invasive, well-tolerated and has a high success rate.
But the need of surgery after PVM is not uncommon, so if a mitral valve res-
tenosis occurred in patients with predictors of surgery, do we repeat PVM or
directly perform RMV?
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Atrial fibrillation (AF) is a major cause of embolic event, but the signifi-
cance of other arrhythmias remains unknown. The purpose of study was to
assess the significance of unexplained stroke in patients who had apparently
only supraventricular tachycardia (SVT).
Population: Unexplained stroke was noted in 26 patients (pts) (group I)
admitted for palpitations and electrophysiological study (EPS); they were
issued from a population of 1002 pts with normal ECG in sinus rhythm, pal-
pitations or tachycardia and with inducible SVT at EPS; 976 pts had no history
of stroke (group II).
Methods: EPS consisted of atrial pacing and programmed atrial stimula-
tion in control state and if necessary after infusion of isoproterenol. Clinical
and electrophysiological data of both groups were studied. Pts with stroke
had a normal carotid ultrasound study and transcranial Doppler ultrasonog-
raphy.
Results: Pts with unexplained stroke represent 2.5 % of population with
SVT. They were older than remaining pts without stroke (65±10 vs 50±19
years) (p 0.001). They have more frequently associated heart disease (8/26,
31 % vs 37/976, 4 %) (p < 0.001). Male gender was more frequent in group
I (16/26, 60 %) than in group II (355/956, 37 %) (p< 0.05). Typical AV
node re-entrant tachycardia was noted in 17 group I pts (65 %) and 693/976
(68 %) (NS); AV re-entrant tachycardia associated with a concealed acces-
sory pathway was noted in 2 group I pts (8 %) and 168 group I pts (17 %)
(NS); atypical AV node re-entrant tachycardia was more frequent in group
I (7/26, 27 %) than in group II (115/976, 12 %) (p<0.05). AF induction was
more frequent in group I (6/26, 23 %) than in group II (35/976, 3.5 %) (p<
0.001). Ablation was performed in 6 group I pts; one of them died from
another stroke; another one died suddenly; another one developed a perma-
nent AF.
Conclusions: Old age, male gender, associated heart disease, and induction
of atrial fibrillation were significant factors associated with the history of
stroke in pts with SVT. They have a risk of adverse events during the follow-
up. However, unexplained stroke was a rare event in patients with paroxysmal
SVT, noted in 2.5 % of this population.
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Introduction: Brain natriuretic peptide (BNP) is released by the left ven-
tricle (LV) in response to increase LV wall stress and is associated with symp-
toms and outcome in aortic stenosis (AS). However, the relation between
BNP, LV filling pressure and left atrial (LA) volume has been poorly exam-
ined in AS. This study was undertaken to assess the determinants of BNP level
in AS.
Method and results: Two-dimensional, tissue Doppler imaging and
Doppler transthoracic echocardiography were performed in 34 consecutive
patients with severe AS (72±12 years, 62% of male, aortic valve area
(AVA), 0.67±0.2 cm2, mean gradient, 45±13mmHg). Concomitantly, plasma
BNP level was measured. Mean plasma level BNP was 325±572pg/ml. BNP
was significantly higher in patients with reduced LV systolic function (LV
ejection fraction ≤ 60%, n=22; 595±869 vs. 178±235pg/ml, p=0.04),
increased indexed LA volume (≥ 40ml/m2, n=21; 454±686 vs. 125±210pg/
ml, p=0.026) and increased LV filling pressure (E/Ea ratios: septal ≥ 15,
n=17, 562±738 vs. 108±117pg/ml, p=0.004; lateral ≥ 11, n=14, 626±800 vs.
137±139, p=0.02). There were good correlations between BNP and LV and
LA ejection fraction, (r=-0.40, p=0.0035 and r=-0.45, p=0.01), indexed LA
volume (r=0.48, p=0.0049) and with septal and lateral E/Ea ratios (r=0.69,
p<0.0001 and r=0.50, p=0.0054). However, there was lower correlation
between BNP and AVA (r=0.33, p=0.047). After adjustment for age and LV
ejection fraction, multivariate analysis showed that E/Ea septal (p=0.0005)
or lateral (p=0.048) ratios and indexed LA volumes (p=0.006) remained
associated with BNP. Furthermore, symptomatic patients (n=24) had signif-
icantly higher BNP level (427±654 vs.78±112pg/ml, p=0.009) and E/Ea
septal (25±14 vs. 12±7, p=0.01) and lateral ratios (15±7 vs. 10±5, p=0.01)
than asymptomatic patients.
Conclusion: This study shows that BNP release is mainly determined by
both LV and LA function in patients with AS. In this population, BNP level
reflects the ventricular and atrial consequences of increased afterload rather
than the severity of stenosis.
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